HUMEN

Upscaling human insulin-producing beta cell production by efficient differentiation and expansion of endoderm progenitors

Coordinatore	KOBENHAVNS UNIVERSITET    more  Organization address postcode: 1017 contact info Titolo: Mr. Nome: Bjarne Friis Cognome: Ploumark Email: send email Telefono: +45 35322712
Nazionalità Coordinatore	Denmark [DK]
Totale costo	7˙860˙730 €
EC contributo	5˙962˙644 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-01-01   -   2017-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	KOBENHAVNS UNIVERSITET	DK	coordinator	1˙935˙725.00
2	THE UNIVERSITY OF EDINBURGH  Organization address address: OLD COLLEGE, SOUTH BRIDGE city: EDINBURGH postcode: EH8 9YL contact info Titolo: Ms. Nome: Angela Cognome: Noble Email: send email Telefono: +44 131 650 9024 Fax: +44 131 651 4028	UK (EDINBURGH)	participant	914˙892.00
3	MATERIOMICS BV  Organization address address: PROFESSOR BRONKHORSTLAAN 10 D city: BILTHOVEN postcode: 3723 MB contact info Titolo: Mr. Nome: Frank-Jan Cognome: Van Der Velden Email: send email Telefono: +31 653905464	NL (BILTHOVEN)	participant	537˙965.00
4	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.  Organization address address: Hofgartenstrasse 8 city: MUENCHEN postcode: 80539 contact info Titolo: Dr. Nome: Susanne Cognome: Schneider Email: send email Telefono: +49 6032 705 1302	DE (MUENCHEN)	participant	514˙700.00
5	UPPSALA UNIVERSITET  Organization address address: SANKT OLOFSGATAN 10 B city: UPPSALA postcode: 751 05 contact info Titolo: Mrs. Nome: Birgitta Cognome: Gustavsson Email: send email Telefono: +46 18 4715029 Fax: +46 18 4715077	SE (UPPSALA)	participant	503˙369.00
6	HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH  Organization address address: Ingolstaedter Landstrasse 1 city: MUENCHEN postcode: 85764 contact info Titolo: Dr. Nome: Jürgen Cognome: Ertel Email: send email Telefono: +49 89 3187 3022	DE (MUENCHEN)	participant	485˙927.00
7	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Mr. Nome: Téva Cognome: West Email: send email Telefono: 33140784925 Fax: 33140784998	FR (PARIS)	participant	441˙020.00
8	CYTOO SA  Organization address address: PARVIS LOUIS NEEL 7 BHT BATIMENT 52 city: GRENOBLE postcode: 38000 contact info Titolo: Mrs. Nome: Laurence Cognome: Fayand Email: send email Telefono: +33 438 88 4744	FR (GRENOBLE)	participant	423˙560.00
9	MILTENYI BIOTEC GMBH  Organization address address: FRIEDRICH EBERT STRASSE 68 city: BERGISCH GLADBACH postcode: 51429 contact info Titolo: Dr. Nome: Miriam Cognome: Haak Email: send email Telefono: +49 2204 8306 4507	DE (BERGISCH GLADBACH)	participant	205˙486.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Despite progress in producing beta cells from human pluripotent stem cells (hPSCs) in recent years, full differentiation cannot be obtained in vitro. The HumEn project hypothesises that a fundamental understanding of the coupling between endodermal progenitor expansion and differentiation is relevant for elucidating how to a) generate glucose-responsive beta cells from hPSCs in vitro, and b) generate sufficient number of beta cells to meet future clinical needs in cell therapy in diabetes. Thus, the overall aim of HumEn is to identify, understand, and expand human endodermal progenitors as a consistent and renewable source of cells for pancreatic beta cells differentiation. We will focus on precursors from two stages of pancreatic differentiation; anterior definitive endoderm (ADE) and pancreatic endoderm (PE) progenitors, providing mechanistic insight into the signalling pathways and downstream targets that control their expansion and functional maturation into human beta cells. Rigorous in vitro (regulated insulin-release) and in vivo (protection against experimentally induced diabetes in mice) testing of insulin-producing cells will ensure a functional end product. The consortium proposes to address these problems by a unique combination of models and experimental approaches, including genetic, surface/biomaterial screens (3D), and cell surface antibody screens as well as cell signalling-to-transcription factor/chromatin effectors. In the end, HumEn aims to deliver a reliable and scalable protocol for directed differentiation of hPSCs into bona fide beta cells. The results of the project will not only provide answers to fundamental questions, but also deliver new concepts and knowledge of general importance for coordination of cell cycle progression and regulation of cell fate specification in stem cells/progenitors. HumEn is highly innovative and carries excellent potential for translational output.'